Printer Friendly

IDT Divests Micro Networks Business.

Cash Transaction Further Focuses Company on Mixed Signal Solutions for Communications, Computing and Consumer Markets

SAN JOSE, Calif. -- IDT([R])(Integrated Device Technology, Inc.)(NASDAQ:IDTI), a leading provider of essential mixed signal semiconductor solutions that enrich the digital media experience, today announced it has signed an agreement to divest its Micro Networks business to Spectrum Control, Inc. for approximately $13 million. The transaction, which has already received approval by the IDT Board of Directors, is expected to close by the end of November.

"Our Micro Networks business has been a stable business for IDT for many years. However, we continue to sharpen our focus on analog-intensive, mixed-signal solutions for the communications, computing and consumer markets. This divestiture is a great outcome for Micro Networks employees and provides funds for use in faster growing businesses that are better aligned with our strategy," said Dr. Ted Tewksbury, IDT president and CEO.

Signal Hill acted as advisors for IDT on the transaction.

About IDT

With the goal of continuously improving the digital media experience, IDT integrates its fundamental semiconductor heritage with essential innovation, developing and delivering low-power, mixed signal solutions that solve customer problems. Headquartered in San Jose, Calif., IDT has design, manufacturing and sales facilities throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market([R]) under the symbol "IDTI." Additional information about IDT is accessible at

IDT and the IDT logo are trademarks or registered trademarks of Integrated Device Technology, Inc. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 23, 2009
Previous Article:Nereus Pharmaceuticals Presents Positive Interim Data from the ADVANCE Study, a Randomized Phase 2 Clinical Trial of Plinabulin (NPI-2358) in...
Next Article:ManTech to Offer Certifications from International Council on Systems Engineering.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters